NextCure Future Growth

Future criteria checks 0/6

NextCure is forecast to grow earnings and revenue by 5.6% and 84.9% per annum respectively while EPS is expected to grow by 37.4% per annum.

Key information

5.6%

Earnings growth rate

37.4%

EPS growth rate

Biotechs earnings growth	27.5%
Revenue growth rate	84.9%
Future return on equity	n/a
Analyst coverage	Low
Last updated	08 Nov 2024

Recent future growth updates

Recent updates

NextCure (NXTC) Presents at 7th Annual Truist Securities Life Sciences Summit - Slideshow

May 10

NextCure EPS misses by $0.01

May 06

Here's What NextCure, Inc.'s (NASDAQ:NXTC) Shareholder Ownership Structure Looks Like

Feb 12

NextCure's (NASDAQ:NXTC) Shareholders Are Down 80% On Their Shares

Jan 08

NextCure provides update on NC318 clinical program

Dec 17

Earnings and Revenue Growth Forecasts

NasdaqGS:NXTC - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	N/A	-44	-40	N/A	1
12/31/2025	N/A	-40	-33	N/A	3
12/31/2024	N/A	-54	-18	N/A	3
9/30/2024	N/A	-59	-45	-45	N/A
6/30/2024	N/A	-61	-46	-46	N/A
3/31/2024	N/A	-64	-51	-51	N/A
12/31/2023	N/A	-63	-54	-53	N/A
9/30/2023	N/A	-66	-53	-51	N/A
6/30/2023	N/A	-70	-55	-53	N/A
3/31/2023	N/A	-70	-55	-53	N/A
12/31/2022	N/A	-75	-56	-54	N/A
9/30/2022	N/A	-74	-61	-58	N/A
6/30/2022	N/A	-73	-58	-56	N/A
3/31/2022	N/A	-73	-61	-59	N/A
12/31/2021	N/A	-69	-60	-57	N/A
9/30/2021	N/A	-68	-53	-50	N/A
6/30/2021	N/A	-66	-57	-53	N/A
3/31/2021	N/A	-63	-55	-48	N/A
12/31/2020	22	-37	-52	-45	N/A
9/30/2020	24	-32	-56	-49	N/A
6/30/2020	26	-24	-47	-41	N/A
3/31/2020	27	-18	-43	-39	N/A
12/31/2019	6	-34	-39	-36	N/A
9/30/2019	4	-30	-8	-3	N/A
6/30/2019	3	-27	-4	0	N/A
3/31/2019	1	-24	2	6	N/A
12/31/2018	N/A	-23	5	8	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NXTC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NXTC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NXTC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NXTC is forecast to have no revenue next year.

High Growth Revenue: NXTC is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if NXTC's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/22 01:44
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NextCure, Inc. is covered by 11 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Aydin Huseynov	Benchmark Company
Alec Stranahan	BofA Global Research
null null	BTIG

NextCure Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased by 25% to US$4.33

Price target decreased by 25% to US$4.33

Price target increased to US$6.67

Price target decreased to US$5.80

Price target decreased to US$6.25

Price target increased to US$14.14

Recent updates

NextCure, Inc. Announces Acceptance of IND Application for LNCB74

NextCure, Inc. Announces the Presentation of Preclinical Data Demonstrating That Treatment with Nc605, A Novel Anti-Siglec-15 (S15) Antibody

Here's Why We're Watching NextCure's (NASDAQ:NXTC) Cash Burn Situation

NextCure, Inc. Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo At Society for Immunotherapy of Cancer Annual Meeting

Insufficient new directors

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

NextCure, Inc. Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024

New major risk - Revenue and earnings growth

NextCure, Inc., Annual General Meeting, Jun 20, 2024

NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024

NextCure, Inc. Appoints Rakesh Dixit to Scientific Advisory Board

New major risk - Revenue and earnings growth

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders

Nextcure, Inc. Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury

Nextcure, Inc. Provides Year-End Clinical Pipeline Updates

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

NextCure, Inc. Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML

NextCure, Inc. Announces Presentation of New Preclinical Data Demonstrate Treatment with NC605

NextCure, Inc. Presents Preclinical Data on Nc181, A Novel Therapeutic Candidate Targeting Apoe4, for the Treatment of Alzheimer's Disease

Will NextCure (NASDAQ:NXTC) Spend Its Cash Wisely?

Price target decreased by 25% to US$4.33

NextCure, Inc. Announces Resignation of Garry A. Nicholson as from the Board of Directors

Price target decreased by 25% to US$4.33

Is NextCure (NASDAQ:NXTC) In A Good Position To Deliver On Growth Plans?

Price target increased to US$6.67

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

Price target decreased to US$5.80

NextCure Presents Initial Data from Clinical Trial of NC762 and a Trial in Progress Poster for NC410 Combo at the 2022 Society for Immunotherapy of Cancer Annual Meeting

Price target decreased to US$6.25

NextCure, Inc. Appoints Lisa M. Coussens to Scientific Advisory Board

NextCure, Inc. Announces Initiation of Phase 1b/2 Clinical Trial to Evaluate NC410 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Immune Checkpoint Refractory or Naïve Solid Tumors

Estimating The Intrinsic Value Of NextCure, Inc. (NASDAQ:NXTC)

Price target increased to US$14.14

NextCure GAAP EPS of -$0.59

NextCure, Inc. Presents NC410 Data at the Extracellular Matrix Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM

Nextcure, Inc. Appoints Dr. Segal to Its Scientific Advisory Board

High number of new directors

Now 23% undervalued after recent price drop

We're Not Very Worried About NextCure's (NASDAQ:NXTC) Cash Burn Rate

NextCure, Inc., Annual General Meeting, Jun 23, 2022

High number of new directors

NextCure and the National Cancer Institute Announce Preclinical Data in Journal of Clinical Investigation

NextCure, Inc. and Collaborators Provide Data on Targets in Development at American Society of Hematology Annual Meeting

Price target decreased to US$16.75

High number of new directors

Independent Director Xiaoxing Xu has left the company

NextCure: Large Upside With Downside Protected By Cash Pile

NextCure, Inc.(NasdaqGS:NXTC) dropped from Russell 2500 Growth Index

Nextcure and Collaborators Publish Preclinical Data on Novel Immunomedicine Nc410

NextCure (NXTC) Presents at 7th Annual Truist Securities Life Sciences Summit - Slideshow

NextCure EPS misses by $0.01

Independent Director has left the company

Full year 2020 earnings released: US$1.33 loss per share (vs US$2.15 loss in FY 2019)

Revenue behind estimates

NextCure, Inc. Announces Resignation of Briggs Morrison from the Board of Directors, Effective April 1, 2021

Here's What NextCure, Inc.'s (NASDAQ:NXTC) Shareholder Ownership Structure Looks Like

New 90-day high: US$13.64

The Schall Law Firm Announces the Filing of A Class Action Lawsuit Against Nextcure, Inc

NextCure, Inc. Announces the Appointment of Han Myint as Chief Medical Officer

New 90-day high: US$13.07

NextCure's (NASDAQ:NXTC) Shareholders Are Down 80% On Their Shares

NextCure, Inc. Provides Updates on NC318 Clinical Program

NextCure provides update on NC318 clinical program

Rosen Reminds Nextcure, Inc. Investors of Important November 20 Deadline in Securities Class Action

Earnings beat expectations

New 90-day high: US$11.65

Bernstein Liebhard Reminds Investors of the Deadline to File Lead Plaintiff Motion in Securities Class Action Lawsuit Against Nextcure Inc

Block & Leviton LLP Reminds Investors of Nextcure, Inc. for Violations of the Federal Securities Laws